Precipio

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Precipio (PRPO) reports revenue growth and aims for profitability

Precipio's Q2 performance reflects positive momentum in revenue growth and operational improvements. While challenges like achieving profitability and FDA approval exist, the company's focus on building relationships and scaling up presents opportunities for future growth. Overall, Precipio is well-positioned to achieve its goals and enhance investor relations post-profitability.

Precipio (PRPO) achieves record diagnoses, nears breakeven in Q3 2024

Precipio's Q3 2024 earnings call highlights strong revenue growth, progress towards breakeven, and improved financial stability. While facing challenges in investor relations, the company's focus on education and visibility initiatives shows a proactive approach to addressing concerns. Leveraging key customer relationships and sustainable growth strategies offer promising opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HemeScreen® Technology and Product Line singled out from thousands of products distributed by Fisher Healthcare at recent National Sales Meeting HemeScreen® Technology and Product Line singled out from thousands of products distributed by Fisher Healthcare at recent National Sales Meeting

ThermoFisher Salesforce Votes Precipio's HemeScreen® as “Best New Product”

Customer's initial annual revenue expected at $650K, $2.0M revenue at full capacity Customer's initial annual revenue expected at $650K, $2.0M revenue at full capacity

Precipio Signs Another Major HemeScreen™ Customer

Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity

Precipio Signs Additional Major HemeScreen™ Customer

Precipio, Inc. (NASDAQ:PRPO ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Operator Welcome to the Precipio Shareholder Third Quarter 2022 Shareholder Update Conference Call. All participants will be in listen-only mode.

Precipio, Inc. (PRPO) Q3 2022 Earnings Call Transcript

Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN Assay Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN Assay

Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ET Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ET

Precipio Announces Third Quarter Shareholder Update Call

Adding customer segment exceeding $100M in market potential Adding customer segment exceeding $100M in market potential

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

Precipio continues to build strong team in anticipation of substantial growth in the next 12 months Precipio continues to build strong team in anticipation of substantial growth in the next 12 months

Sharon Robins Joins Precipio's Products Division as Senior Director of Laboratory & Hospital Sales

New technology enables same day test results by eliminating extra confirmation step New technology enables same day test results by eliminating extra confirmation step

Precipio Launches New 1-Step Technology for all HemeScreen Assays

Precipio, Inc. (NASDAQ:PRPO ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Ilan Danieli - Founder, President, CEO & Director Conference Call Participants Operator Welcome to the Precipio Shareholder -- Second Quarter 2022 Shareholder Update Conference Call. (Operator Instructions) Please note that the conference is being recorded.

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2022 Results - Earnings Call Transcript

Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors

Toni-Ann Mills Joins Precipio's Products Division to Lead Channel Partner Training, Learning & Development

Conference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST Conference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST

Precipio Announces Second Quarter Shareholder Update Call

Agreement Enhances Precipio's Product Reach to US Laboratories Agreement Enhances Precipio's Product Reach to US Laboratories

Precipio to distribute HemeScreen® through Fisher Healthcare channel

Meeting Adjourned, new meeting set for July 5th at 10am EDT Meeting Adjourned, new meeting set for July 5th at 10am EDT

Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote

Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations

Keith Meadors Joins Precipio to Lead its Products Division

This Regulatory Approval Opens the Company's Reach to the European Market This Regulatory Approval Opens the Company's Reach to the European Market

Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe

Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential

Precipio Signs First IV-Cell Customer Agreement

NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College , organized by publication Dark Daily, the premier laboratory conference, held April 26th through 28th in New Orleans.

Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2021 Results - Earnings Call Transcript

Conference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST Conference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST

Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call

NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately.

Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced its unaudited and preliminary results for 2021. The Company anticipates posting revenues of $8.9 million, an increase of $2.8 million from 2020, representing a 45% year-over-year increase. Additionally, preliminary Q4-2021 revenues of $2.4 million represent a 25% increase from revenues of $1.9 million in Q4-2020.

Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022

Digital Ally Inc

Seanergy Maritime Hlds

Which penny stocks are you watching right now? The post Best Penny Stocks to Buy Today?

Best Penny Stocks to Buy Today? 3 For Your Watchlist Right Now

New York Cancer & Blood POL will commence the use of HemeScreen in its laboratory New York Cancer & Blood POL will commence the use of HemeScreen in its laboratory

New York State Approves Precipio's HemeScreen for POL clinical use

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q3 2021 Results - Earnings Call Transcript

News for Precipio Stock (PRPO)